CIPLA LTD.

NSE : CIPLABSE : 500087ISIN CODE : INE059A01026Industry : Pharmaceuticals & DrugsHouse : Cipla
BSE760.40-1.8 (-0.24 %)
PREV CLOSE ( ) 762.20
OPEN PRICE ( ) 766.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 566780
TODAY'S LOW / HIGH ( )754.50 782.95
52 WK LOW / HIGH ( )356.75 814.45
NSE760.25-1.85 (-0.24 %)
PREV CLOSE( ) 762.10
OPEN PRICE ( ) 765.95
BID PRICE (QTY) 760.25 (159)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 13741283
TODAY'S LOW / HIGH( ) 754.10 782.90
52 WK LOW / HIGH ( )355.3 814.5
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 17-08 1935
Management Info
Y K Hamied - Chairman Umang Vohra - Managing Director
Registered Office

Address Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg, Lower Parel,
Mumbai,
Maharashtra-400013

Phone 022-24826000 / 022-24826951

Email cosecretary@cipla.com

Website www.cipla.com

Registrars Details
K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, Luxembourg, MCX
NEWS
10Aug Cipla reports 21% rise in Q1 consolida
Cipla has reported results for the first quarter ended June 30, 2020.The..
10Aug Cipla shines on reporting 21% rise in
Cipla is currently trading at Rs. 803.30, up by 74.70 points or 10.25% f..
08Aug Cipla submits newspaper publication
Cipla has submitted newspaper publication.The above information is a par..
27Jul Cipla, Precision Camshafts and Jenburk
Cipla has been granted regulatory approval by the Drug Controller Genera..
27Jul Cipla gains on getting DCGI’s nod to l
Cipla is currently trading at Rs. 669.10, up by 3.60 points or 0.54% fro..
Financials
Rs. in Millions
QTR Jun 20 ANNUAL 20
Net Profit610323181.7
Gross Profit 8324.6 29643.1
Operating Profit 990436001.4
Net Sales 31280.2126591.5
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Alkem Laboratories (BSE)
 2906.70 (4.25%)
M.Cap (Rs. in Cr)34753.96
NGL Fine-Chem (BSE)
 589.85 (20.00%)
M.Cap (Rs. in Cr)364.41
Glaxosmithkline Phar (BSE)
 1523.60 (4.51%)
M.Cap (Rs. in Cr)25810.70
Aarti Drugs (BSE)
 2139.65 (3.16%)
M.Cap (Rs. in Cr)4985.38
Caplin Point Lab (BSE)
 556.80 (9.10%)
M.Cap (Rs. in Cr)4211.79
Shareholding Pattern
PROMOTERS 36.68%
NON-INSTITUTION 23.4%
MUTUAL FUNDS/UTI 16.29%
FI/BANKS/INSURANCE 4.78%
FII 0.01%
GOVERNMENT 0%
ATTENTION INVESTORSKYCIPO
Download Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do’s & Don’t’s) in Vernacular Language :
REGISTRATION NOS.

NSE CM-INZ000234235|NSE F& O - INZ000234235, NSE CD-INZ000234235, BSE CM–INZ000234235 |BSE F & O - INZ000234235|BSE CD- INZ000234235 MCX-SX CM-INZ000234235|MCX-SX F & O - INZ000234235|MCX-SX CD-INZ000234235 NSDL - IN-DP-NSDL-319-2009ROC REG - 21-097912,CDSL : IN-DP-242-2016

INVESTOR PROTECTION

Compliance officer : Sanjay Jadli, Apurva Mittal, Tel No: 022-40790035,022-40790024, Mobile No: 9152943075,9768009000, E-mail ID: compliance@nnmsecurities.com,cdsl@nnmsecurities.com

Investor grievance : support@nnmsecurities.com

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances

For Lodge the grievances click on https://scores.gov.in

Click/visit on SEBI Complaints Redress System (SCORES) for Procedure for filing of complaints on SCORES and benefits.

Copyright © 2016 NNM Securities.com

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.